Pharma BD Deal Intelligence
Biotech transformation came at high price requiring generics divestiture to fund deal
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Merck KGaA acquired Serono for $13.2B.
Merck KGaA announced it agreed to purchase the majority stake in Serono SA for approximately $13.3 billion, combining Merck pharmaceuticals division with…
Merck KGaA agreed to acquire a majority stake in Serono for $13.3 billion, creating Europe largest biotechnology company with an enhanced pharmaceutical…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Merck KGaA acquired Serono International S.A. for CHF 16.6 billion (~$13.3 billion) in an all-cash transaction, gaining a leading biotech company focused on fertility, multiple sclerosis (Rebif), and growth disorders. The deal transformed Merck from a mid-sized chemicals/pharma company into a top-20 global pharmaceutical player.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck KGaA / Serono SA (this deal) | 2006 | $13.2B | 74 |
| Merck KGaA / Millipore Corporation | 2010 | $7.2B | 88 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Merck KGaA / Versum Materials | 2019 | $5.8B | 80 |
| Merck KGaA / SpringWorks Therapeutics | 2025 | $3.4B | 72 |
| Merck KGaA / Threshold Pharmaceuticals, Inc. | 2012 | $550M | — |
| Merck KGaA / Debiopharm | 2021 | $1.1B | — |
← Browse all deals · How we score deals
More: 2006 deals · Merck KGaA deals · Neurology deals